DK2124997T3 - Anvendelse af IL-1-antagonister til behandling af gigt og pseudogigt - Google Patents

Anvendelse af IL-1-antagonister til behandling af gigt og pseudogigt

Info

Publication number
DK2124997T3
DK2124997T3 DK07839723.9T DK07839723T DK2124997T3 DK 2124997 T3 DK2124997 T3 DK 2124997T3 DK 07839723 T DK07839723 T DK 07839723T DK 2124997 T3 DK2124997 T3 DK 2124997T3
Authority
DK
Denmark
Prior art keywords
gout
antagonists
pseudo
treatment
Prior art date
Application number
DK07839723.9T
Other languages
English (en)
Inventor
Catherine Vicary
Scott Mellis
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of DK2124997T3 publication Critical patent/DK2124997T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK07839723.9T 2006-10-20 2007-10-19 Anvendelse af IL-1-antagonister til behandling af gigt og pseudogigt DK2124997T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85338506P 2006-10-20 2006-10-20
PCT/US2007/022377 WO2008051496A2 (en) 2006-10-20 2007-10-19 Use of il-1 antagonists to treat gout and pseudogout

Publications (1)

Publication Number Publication Date
DK2124997T3 true DK2124997T3 (da) 2012-08-27

Family

ID=39322920

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07839723.9T DK2124997T3 (da) 2006-10-20 2007-10-19 Anvendelse af IL-1-antagonister til behandling af gigt og pseudogigt

Country Status (20)

Country Link
US (1) US20080300185A1 (da)
EP (1) EP2124997B1 (da)
JP (1) JP5397948B2 (da)
CN (1) CN101528252B (da)
AU (1) AU2007309470B2 (da)
BR (1) BRPI0718469A2 (da)
CA (1) CA2666629C (da)
DK (1) DK2124997T3 (da)
ES (1) ES2389314T3 (da)
HR (1) HRP20120896T1 (da)
IL (1) IL197832A (da)
MX (1) MX2009004051A (da)
NZ (1) NZ575972A (da)
PL (1) PL2124997T3 (da)
PT (1) PT2124997E (da)
RS (1) RS52538B (da)
RU (1) RU2450824C2 (da)
SG (1) SG175642A1 (da)
SI (1) SI2124997T1 (da)
WO (1) WO2008051496A2 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101945891A (zh) 2007-12-20 2011-01-12 爱克索马技术有限公司 治疗痛风的方法
WO2010071865A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
US20100160351A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
WO2011032175A1 (en) 2009-09-14 2011-03-17 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto
CA2829101C (en) 2011-03-11 2019-08-20 Twi Biotechnology, Inc. Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia
WO2014035361A1 (en) * 2012-08-26 2014-03-06 R-PHARM, CJSC (Closed Joint Stock Company) IL-1β INHIBITOR COMPOSITION AND USE THEREOF
CN105367663A (zh) * 2014-08-31 2016-03-02 复旦大学 一种长效白细胞介素-1受体拮抗剂重组融合蛋白及其制备方法和用途
KR101863604B1 (ko) * 2016-04-08 2018-06-04 한국 한의학 연구원 익지 추출물을 유효성분으로 함유하는 고요산혈증 또는 고요산혈증 관련 대사 장애의 예방, 개선 또는 치료용 조성물
CN110251659A (zh) * 2019-07-03 2019-09-20 安徽省立医院 一种小剂量白细胞介素2在制备治疗慢性痛风药物中的应用
CN116539880B (zh) * 2022-12-05 2023-12-08 四川大学华西医院 检测代谢物和/或组织蛋白的试剂在制备痛风性关节炎筛查试剂盒中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) * 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
WO2004100987A2 (en) * 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat neointimal hyperplasia
US7226553B2 (en) * 2003-07-30 2007-06-05 E. I. Du Pont De Nemours And Company Polymer underwater pelletizer apparatus and process incorporating same
US20050129685A1 (en) * 2003-09-18 2005-06-16 Jingtai Cao Use of IL-1 blockers to prevent corneal inflammation and neovascularization
MXPA06014126A (es) * 2004-06-04 2007-07-18 Regeneron Pharma Metodos para utilizar antagonistas il-1 para tratar enfermedades auto-inflamatorias.
ES2373668T3 (es) * 2004-09-17 2012-02-07 Kissei Pharmaceutical Co., Ltd. Derivado de nucleósido de purina modificado en la posición 8 y uso medicinal del mismo.
WO2006084145A2 (en) * 2005-02-02 2006-08-10 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to reduce c-reactive protein
WO2007077042A1 (en) * 2006-01-06 2007-07-12 Topotarget Switzerland Sa New method for the treatment of gout or pseudogout

Also Published As

Publication number Publication date
CN101528252A (zh) 2009-09-09
JP2010506936A (ja) 2010-03-04
WO2008051496A8 (en) 2009-07-30
CA2666629C (en) 2016-08-16
NZ575972A (en) 2011-01-28
ES2389314T3 (es) 2012-10-25
BRPI0718469A2 (pt) 2014-01-21
EP2124997A2 (en) 2009-12-02
PT2124997E (pt) 2012-10-24
RU2009118962A (ru) 2010-11-27
RU2450824C2 (ru) 2012-05-20
JP5397948B2 (ja) 2014-01-22
MX2009004051A (es) 2009-05-11
CA2666629A1 (en) 2008-05-02
PL2124997T3 (pl) 2013-01-31
EP2124997B1 (en) 2012-08-08
CN101528252B (zh) 2014-05-28
WO2008051496A3 (en) 2008-10-30
AU2007309470B2 (en) 2013-05-23
SI2124997T1 (sl) 2012-11-30
AU2007309470A1 (en) 2008-05-02
SG175642A1 (en) 2011-11-28
US20080300185A1 (en) 2008-12-04
IL197832A0 (en) 2011-08-01
WO2008051496A2 (en) 2008-05-02
RS52538B (en) 2013-04-30
HRP20120896T1 (hr) 2012-12-31
IL197832A (en) 2014-06-30

Similar Documents

Publication Publication Date Title
DK2124997T3 (da) Anvendelse af IL-1-antagonister til behandling af gigt og pseudogigt
DK1954140T3 (da) Glycerollevulinatketaler og deres anvendelse
DK2118140T3 (da) Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
DK2124999T3 (da) Activin-actrii antagonister og anvendelser til behandling af anæmi
DK2079485T3 (da) Phenylpropionamidforbindelser og anvendelsen deraf
DK1969391T3 (da) Tyndfilm emitter-absorber indretning og fremgangsmåde
DK1937276T3 (da) Forbedret testosterongel og fremgangsmåde til anvendelse deraf
DK1951866T3 (da) Delta-9-elongaser og anvendelse heraf til fremstilling af flerumættede fedtsyrer
DK2059535T3 (da) Prlr-specifikt antistof og anvendelser deraf
DK1765376T3 (da) Topiske sammensætninger og anvendelse deraf til behandling af epitel-relaterede tilstande
DK1894567T3 (da) Ledsagende farmaceutiske midler og anvendelse deraf
DK2185164T3 (da) Sammensætning og terapeutisk antitumorvaccine
DK2147315T3 (da) Diabetesrelaterede biomarkører og fremgangsmåder til anvendelse deraf
DK3321359T3 (da) Variante former af uratoxidase og anvendelse deraf
DK2147096T3 (da) Modificerede faktor-VII-polypeptider og anvendelser deraf
DK2001556T3 (da) Thioninium-forbindelser og anvendelse deraf
DK2114419T3 (da) Natriummetaarsenit til anvendelse i behandling af smerte og inflammation
DK2342233T3 (da) Anti-CXCR4-antistoffer og anvendelse deraf i behandling af cancer
DK2170827T3 (da) Indolin-2-oner og aza-indolin-2-oner
DK2142529T3 (da) Trpv1-antagonister og anvendelser deraf
DK2038275T3 (da) Ny pyridazinforbindelse og anvendelse heraf
DK2069467T3 (da) Adskillende sammensætninger og fremgangsmåder til anvendelse
DK2029799T3 (da) Termostabile proteiner og fremgangsmåder til fremstilling og anvendelse heraf
DE602005020202D1 (de) Getrennter Steckverbinder und Verbindereinrichtung
DK2081955T3 (da) Metastinderivater og anvendelse deraf